Stroke Clinical Trials

Find Stroke Clinical Trials Near You

Assessment of the Safety and Effectiveness of the VARIPULSE™ Catheter System in the Treatment of Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein (With or Without Posterior Wall Isolation) and Superior Vena Cava Isolation: A Randomized Controlled Trial

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to assess how safe VARIPULSE catheter system is for treatment of a heart rhythm disease called persistent atrial fibrillation (PsAF) in participants who are having a catheter ablation procedure (treat heart rhythm disease). This includes isolation of pulmonary vein and superior vena cava (heart veins; pulmonary vein isolation \[PVI\] and superior vena cava isolation \[SVCI\]), with or without another technique called posterior wall isolation (PWI). Also, to assess how safe it is for participants who are having a catheter ablation procedure and at the same time receiving another procedure called left atrial appendage occlusion (LAAO; to reduce stroke risk). Additionally, to assess how well VARIPULSE catheter system works over a long period of time for treatment of PsAF in participants undergoing catheter ablation for PVI, SVCI and SVCI+PWI.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Participant has been diagnosed with symptomatic persistent atrial fibrillation (PsAF), which is defined as continuous atrial fibrillation (AF) sustained beyond 7 days in duration and less than 365 days in duration, documented by: i. A physician's note documenting diagnosis of symptomatic PsAF, as defined above; and ii. Two electrocardiograms (ECGs) showing continuous AF, with electrocardiogram taken at least 7 days apart (electrocardiograms cannot be greater than (\>) 365 days prior to enrollment); or iii. A 24-hour arrhythmia monitor documenting continuous AF within the last 365 days

• Participant is aged 18 - 80 years at the time of informed consent

• Participant is willing and capable of providing informed consent

• Participant is able and willing to comply with all pre-, post- and follow-up testing and requirement

⁃ Left atrial appendage occlusion (LAAO) concomitant subset:

⁃ \- Participant is clinically indicated for a LAAO procedure

Locations
United States
Arkansas
Arrhythmia Research Group
RECRUITING
Jonesboro
Arizona
Pima Heart and Vascular
RECRUITING
Tucson
New York
Albert Einstein College Of Medicine - Montefiore Medical Center
RECRUITING
The Bronx
Contact Information
Primary
Narvelle Delabruere
NDelabru@its.jnj.com
949-933-1710
Backup
Josiah M Gillespie
jgille12@its.jnj.com
405-924-0777
Time Frame
Start Date: 2026-08-24
Estimated Completion Date: 2031-08-24
Participants
Target number of participants: 1070
Treatments
Experimental: VARIPULSE Catheter System: PVI and SVCI
Participants with persistent atrial fibrillation (PsAF) undergoing catheter ablation for the first-time with the VARIPULSE Catheter System will undergo the ablation procedure for PVI and SVCI.~Additionally, a subset of participants will undergo a concomitant left atrial appendage occlusion (LAAO) procedure. All participants will be followed for up to 36 months post procedure.
Experimental: VARIPULSE Catheter System: PVI and SVCI + PWI
Participants with PsAF undergoing catheter ablation for the first-time with VARIPULSE catheter system will undergo the ablation procedure for PVI and SVCI along with posterior wall isolation (PWI). Additionally, a subset of participants will undergo a concomitant LAAO procedure. All participants will be followed for up to 36 months post procedure.
Sponsors
Leads: Biosense Webster, Inc.

This content was sourced from clinicaltrials.gov